Press Releases VBI Vaccines Inc.

Equities

VBIV

CA91822J2020

Delayed Nasdaq Other stock markets 01:17:01 30/04/2024 am IST			5-day change	1st Jan Change
0.5543 ^USD	-3.43%		-9.65%	-7.27%

16/04	VBI Vaccines Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
15/04	North American Morning Briefing : Stock Futures -2-	DJ

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

VBI Vaccines : 2023 Annual Report	17/04	PU
VBI Vaccines Reports Full Year 2023 Financial Results	16/04	BU
VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	12/04	BU
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	10/04	BU
VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma	03/04	BU
VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform - VBI Vaccines	03/04	AQ
VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform	02/04	BU
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results	25/03	AQ
Brii Biosciences Announces Agreements To Acquire VBI Vaccines' IP Rights In BRII-179	05/03	AQ
Thinking about buying stock in Arena Group, Dunxin Financial Holdings, Nano-X Imaging, VBI Vaccines, or SuRo Capital?	15/02	PR
VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences	14/02	BU
VBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology Annual Meeting	21/11	AQ
VBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting	20/11	BU
VBI Vaccines Reports Third Quarter 2023 Financial Results	15/11	BU
VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program - VBI Vaccines	27/23/27	AQ
VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program	26/23/26	BU
VBI Vaccines Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers against Variants of Concern	28/23/28	AQ
CapitalGainsReport: Nano-Cap Stocks Momentum Watchlist (MGRX, VBIV, GWAV, HIMS)	28/23/28	AQ
VBI Vaccines’ Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of Concern	27/23/27	BU
VBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM - VBI Vaccines	07/23/07	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases VBI Vaccines Inc.

Equities

VBIV

CA91822J2020

Press Releases

Filters